Epigenetic Contribution to the Pathogenesis of Diabetic Nephropathy in Qatari Population

NCT02316522 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 158

Last updated 2022-05-02

No results posted yet for this study

Summary

The main objective is to study the epigenetic contribution to the pathophysiology of diabetic nephropathy in Qatari population.

Conditions

Sponsors & Collaborators

  • Hamad Medical Corporation

    collaborator INDUSTRY
  • Weill Cornell Medical College in Qatar

    collaborator OTHER
  • Weill Medical College of Cornell University

    lead OTHER

Principal Investigators

  • Charbel Abi Khalil, MD · Weill Cornell Medical College in Qatar

Eligibility

Min Age
18 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2014-10-23
Primary Completion
2018-04-09
Completion
2018-04-09

Countries

  • Qatar

Study Locations

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02316522 on ClinicalTrials.gov